AbbVie agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid NaV1.8 inhibitor pain candidates:
HSK55718 (Phase 1 IV) and HSK51155 (preclinical oral).
The deal includes $10 million in near-term milestones and up to $705 million in additional milestones, plus high-single-digit royalties on net sales.
AbbVie will fund R&D costs through clinical proof of concept; Haisco retains Greater China rights.
Announced via April 13 Chinese filing, aligning with Haisco's international expansion strategy.
Competitive landscape includes Vertex's approved Journavx and Eli Lilly's acquisition in NaV1.8 space.14
Sources:
1. https://www.fiercebiotech.com/biotech/abbvie-inks-715m-deal-chinese-biotech-haisco-two-acute-pain-assets